In Phase C, members will acquire ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Contributors will get treatment right up until sickness progression or the contributors are unable to tolerate the study drugs. 88 These preclinical studies offer paradigms for long term clinical trials in https://abbv-744-in-clinical-tria57902.onzeblog.com/31960168/the-best-side-of-abbv-744-clinical-trial-phase-2-data